Carbone LD, et al. - Via a study on 131,793 postmenopausal women users, the researchers determined the relationship of pharmacological inhibitors of the renin-angiotensin-aldosterone system (RAAS) to osteoporosis and studied the simultaneous measurements of both incident fractures and bone mineral density (BMD). No significant association was found between RAAS inhibitor use and all fractures including hip BMD. In the first 3 years of use, an increased risk for fracture among new postmenopausal women user was noted by the use of RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers. However, reduced risk was noted in long-term use (> 3 years).